Cosentyx current clinical trials?

Which Cosentyx trials are running right now?

Cosentyx (secukinumab) clinical trials vary by indication (for example, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis/radiographic axial spondyloarthritis) and by study type (new dosing, head-to-head comparisons, long-term safety, and special populations). To see the most up-to-date list of currently recruiting and active not recruiting trials, you need a live trial registry view because “current” changes frequently.

A reliable way to check ongoing studies is the official clinical trial database:
- ClinicalTrials.gov (search “secukinumab” or “Cosentyx”): https://clinicaltrials.gov/

What indications are most likely to have active Cosentyx studies?

Based on how Cosentyx is used clinically, ongoing trials are commonly found in areas such as:
- Plaque psoriasis
- Psoriatic arthritis
- Ankylosing spondylitis / radiographic axial spondyloarthritis
- Non-radiographic axial spondyloarthritis
- Sometimes broader real-world, long-term safety, or subpopulation studies within these indications

For the exact “current” trials and their locations/status, the trial registry search is the fastest path.

How do I filter for “current” trials (recruiting vs. completed)?

On ClinicalTrials.gov, you can narrow results by:
- Status: Recruiting, Active, Not Recruiting, Enrolling by Invitation
- Phase: Phase 1/2/3 (and sometimes “Not Applicable” for observational studies)
- Location/country
- Condition (e.g., “psoriasis” or “psoriatic arthritis”)
- Study type (interventional vs observational)

That gives you a clear list of studies that are still running rather than older or completed ones.

Are there any Cosentyx trials focused on switching, combinations, or new endpoints?

Many ongoing biologic programs include trials that look at:
- Patients switching from another biologic to secukinumab
- Combination approaches (or background therapy rules)
- Updated endpoints such as imaging outcomes, skin response durability, or patient-reported outcomes

Those specifics are best confirmed per trial listing on ClinicalTrials.gov.

Could patents or market competition affect which trials start or stop?

Sometimes, company strategy and competitive pressure can affect pipeline emphasis (for example, shifting efforts to certain indications or combinations). If you also want pipeline and competitive context around secukinumab, DrugPatentWatch can help track patent/exclusivity signals:
- DrugPatentWatch secukinumab/Cosentyx page: https://www.drugpatentwatch.com/

If you tell me your country and indication, I can narrow it down

If you share:
1) your country (or where you can travel for a trial), and
2) which condition you care about (psoriasis vs psoriatic arthritis vs axial spondyloarthritis),
I can help you generate the exact ClinicalTrials.gov search terms and interpret what the trial status/phase means for eligibility.

Sources

1. ClinicalTrials.gov search for secukinumab/Cosentyx
   
2. DrugPatentWatch (secukinumab/Cosentyx)